Australia restricts use of cough and cold medicines in children; new labelling required from 1 Sept
This article was originally published in SRA
Drug sponsors marketing cough and cold medicines in Australia will have to start amending their labelling and packaging from 1 September onwards to state that such products should not be given to children below six years of age1. Labels will also have to reflect that for children aged six to 11 years, these medicines should only be allowed on the advice of a doctor, pharmacist or nurse practitioner.
You may also be interested in...
Citing challenges posed by the COVID-19 pandemic, EU regulators have extended the deadline for companies to finish nitrosamine-related risk evaluations.
The Australian health care products regulator is inviting feedback on proposed measures to clarify the boundary for software-based products that are captured under the regulatory framework for medical devices.
A draft EU guideline explains how companies can ensure that data from ongoing clinical trials remains relevant for regulatory decision-making despite problems posed by the COVID-19 pandemic.